Moderna's COVID-19 Vaccine Booster US FDA Panel Nod Driven By Pragmatism

 
• By Sue Sutter

Despite lack of enthusiasm with immunobridging study data, the panel endorsed emergency use in certain at-risk populations, in part because it would be hard to turn down the Moderna booster when an identical EUA had been issued for Pfizer/BioNTech's mRNA vaccine.

Against a wall
FDA panel members may have felt like they'd been backed into a wall with the Moderna booster EUA recommendation so closely following the Pfizer/BioNTech authorization. • Source: Alamy

More from Vaccines

More from Pink Sheet